Literature DB >> 32412907

Is there any evidence implying the use of a different criterion for protective anti-HBs titer after HBV vaccination in immunosuppressed patients?

İmran Hasanoğlu1, Rahmet Güner1.   

Abstract

Entities:  

Year:  2020        PMID： 32412907      PMCID： PMC7236648          DOI： 10.5152/tjg.2020.19040

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN： 1300-4948            Impact factor:   1.852


× No keyword cloud information.
  9 in total

Review 1.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  K Rajender Reddy; Kimberly L Beavers; Sarah P Hammond; Joseph K Lim; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

Review 3.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

4.  Hepatitis B vaccines: WHO position paper – July 2017.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-07-07

5.  Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.

Authors:  Bilgehan Aygen; Ahmet Muzaffer Demir; Mahmut Gümüş; Oğuz Karabay; Sabahattin Kaymakoğlu; Aydın Şeref Köksal; İftihar Köksal; Necati Örmeci; Fehmi Tabak
Journal:  Turk J Gastroenterol       Date:  2018-05       Impact factor: 1.852

Review 6.  Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.

Authors:  Sonali Paul; Aaron Dickstein; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Hepatology       Date:  2017-06-22       Impact factor: 17.425

Review 7.  Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Authors:  Adrian M Di Bisceglie; Anna S Lok; Paul Martin; Norah Terrault; Robert P Perrillo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

8.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Authors:  Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang
Journal:  Clin Infect Dis       Date:  2014-02       Impact factor: 9.079

9.  Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Sarah Schillie; Claudia Vellozzi; Arthur Reingold; Aaron Harris; Penina Haber; John W Ward; Noele P Nelson
Journal:  MMWR Recomm Rep       Date:  2018-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.